MUC2 and cholangiocarcinoma: Furthermore, Yamashita et al [13] accomplished an immunohistological analysis in patients with hepatolithiasis and intrahepatic bile-duct carcinoma and suggest that the different expression and production of mucin carbohydrates [Tn, sialosyl-Tn(STn), and T antigens] and core proteins [MUC1-apomucin-related antigen (ARA) and MUC2-ARA] by bile-duct cystadenocarcinomas and cholangiocarcinomas are markers of a differing prognosis.